Cargando…

Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report

High-energy trauma with severe bone fractures can be complicated by infection, leading to the development of osteomyelitis. Pseudomonas aeruginosa is an important causative agent of such infections because of its high virulence profile and ability to develop resistance against a wide range of antimi...

Descripción completa

Detalles Bibliográficos
Autores principales: Racenis, Karlis, Rezevska, Dace, Madelane, Monta, Lavrinovics, Ervins, Djebara, Sarah, Petersons, Aivars, Kroica, Juta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081798/
https://www.ncbi.nlm.nih.gov/pubmed/35547216
http://dx.doi.org/10.3389/fmed.2022.851310
_version_ 1784703071016714240
author Racenis, Karlis
Rezevska, Dace
Madelane, Monta
Lavrinovics, Ervins
Djebara, Sarah
Petersons, Aivars
Kroica, Juta
author_facet Racenis, Karlis
Rezevska, Dace
Madelane, Monta
Lavrinovics, Ervins
Djebara, Sarah
Petersons, Aivars
Kroica, Juta
author_sort Racenis, Karlis
collection PubMed
description High-energy trauma with severe bone fractures can be complicated by infection, leading to the development of osteomyelitis. Pseudomonas aeruginosa is an important causative agent of such infections because of its high virulence profile and ability to develop resistance against a wide range of antimicrobials quickly. P. aeruginosa biofilms cause treatment failure and relapsing infections. Bacteriophages are viruses that can be used to treat biofilm-associated infections. Moreover, the combination of phages with certain antimicrobials have demonstrated synergistic and additive effects. We present a case of a 21-year-old patient with relapsing multidrug-resistant (MDR) P. aeruginosa femur osteomyelitis that developed after a road accident, with a proximal right femoral Grade III B open fracture and severe soft tissue damage. Despite extensive antimicrobial treatment and multiple surgical interventions with wound debridement, the infection persisted, with subsequent development of femoral osteomyelitis with a fistula. Patient care management included femoral head excision with wound debridement, intravenous (IV) ceftazidime-avibactam, and the local application of the lytic Pseudomonas bacteriophage cocktail BFC 1.10. Nine months after the intervention, the patient did not show any clinical, radiological, or laboratory signs of inflammation; therefore, hip replacement was performed. Nevertheless, recurrent P. aeruginosa infection evolved at the distal side of the femur and was successfully treated with conventional antimicrobials. In this case, wound debridement combined with antibiotics and bacteriophages resulted in bacterial eradication of proximal femoral segment, avoiding leg amputation, but failed to treat osteomyelitis in distal bone segment. An in vitro assessment of the isolated MDR P. aeruginosa strain for biofilm formation and phage susceptibility was performed. Additionally, the antimicrobial effects of ceftazidime-avibactam and BFC 1.10 were determined on planktonic cell growth and bacterial biofilm prevention was evaluated. The isolated bacterial strains were susceptible to the bacteriophage cocktail. Strong biofilm formation was detected 6 h after inoculation. Ceftazidime-avibactam combined with BFC 1.10 was most effective in preventing planktonic cell growth and biofilm formation. In both cases, the required concentration of ceftazidime-avibactam decreased two-fold. This study demonstrates the possible use of bacteriophages and antibiotics in difficult-to-treat bone and soft tissue infections, where the additive effects of phages and antibiotics were observed.
format Online
Article
Text
id pubmed-9081798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90817982022-05-10 Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report Racenis, Karlis Rezevska, Dace Madelane, Monta Lavrinovics, Ervins Djebara, Sarah Petersons, Aivars Kroica, Juta Front Med (Lausanne) Medicine High-energy trauma with severe bone fractures can be complicated by infection, leading to the development of osteomyelitis. Pseudomonas aeruginosa is an important causative agent of such infections because of its high virulence profile and ability to develop resistance against a wide range of antimicrobials quickly. P. aeruginosa biofilms cause treatment failure and relapsing infections. Bacteriophages are viruses that can be used to treat biofilm-associated infections. Moreover, the combination of phages with certain antimicrobials have demonstrated synergistic and additive effects. We present a case of a 21-year-old patient with relapsing multidrug-resistant (MDR) P. aeruginosa femur osteomyelitis that developed after a road accident, with a proximal right femoral Grade III B open fracture and severe soft tissue damage. Despite extensive antimicrobial treatment and multiple surgical interventions with wound debridement, the infection persisted, with subsequent development of femoral osteomyelitis with a fistula. Patient care management included femoral head excision with wound debridement, intravenous (IV) ceftazidime-avibactam, and the local application of the lytic Pseudomonas bacteriophage cocktail BFC 1.10. Nine months after the intervention, the patient did not show any clinical, radiological, or laboratory signs of inflammation; therefore, hip replacement was performed. Nevertheless, recurrent P. aeruginosa infection evolved at the distal side of the femur and was successfully treated with conventional antimicrobials. In this case, wound debridement combined with antibiotics and bacteriophages resulted in bacterial eradication of proximal femoral segment, avoiding leg amputation, but failed to treat osteomyelitis in distal bone segment. An in vitro assessment of the isolated MDR P. aeruginosa strain for biofilm formation and phage susceptibility was performed. Additionally, the antimicrobial effects of ceftazidime-avibactam and BFC 1.10 were determined on planktonic cell growth and bacterial biofilm prevention was evaluated. The isolated bacterial strains were susceptible to the bacteriophage cocktail. Strong biofilm formation was detected 6 h after inoculation. Ceftazidime-avibactam combined with BFC 1.10 was most effective in preventing planktonic cell growth and biofilm formation. In both cases, the required concentration of ceftazidime-avibactam decreased two-fold. This study demonstrates the possible use of bacteriophages and antibiotics in difficult-to-treat bone and soft tissue infections, where the additive effects of phages and antibiotics were observed. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9081798/ /pubmed/35547216 http://dx.doi.org/10.3389/fmed.2022.851310 Text en Copyright © 2022 Racenis, Rezevska, Madelane, Lavrinovics, Djebara, Petersons and Kroica. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Racenis, Karlis
Rezevska, Dace
Madelane, Monta
Lavrinovics, Ervins
Djebara, Sarah
Petersons, Aivars
Kroica, Juta
Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report
title Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report
title_full Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report
title_fullStr Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report
title_full_unstemmed Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report
title_short Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis—A Case Report
title_sort use of phage cocktail bfc 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant pseudomonas aeruginosa femur osteomyelitis—a case report
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081798/
https://www.ncbi.nlm.nih.gov/pubmed/35547216
http://dx.doi.org/10.3389/fmed.2022.851310
work_keys_str_mv AT raceniskarlis useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport
AT rezevskadace useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport
AT madelanemonta useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport
AT lavrinovicservins useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport
AT djebarasarah useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport
AT petersonsaivars useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport
AT kroicajuta useofphagecocktailbfc110incombinationwithceftazidimeavibactaminthetreatmentofmultidrugresistantpseudomonasaeruginosafemurosteomyelitisacasereport